CN103690618A - Pulsatilla chinensis total saponin oral emulsion and preparation method thereof - Google Patents
Pulsatilla chinensis total saponin oral emulsion and preparation method thereof Download PDFInfo
- Publication number
- CN103690618A CN103690618A CN201310059867.XA CN201310059867A CN103690618A CN 103690618 A CN103690618 A CN 103690618A CN 201310059867 A CN201310059867 A CN 201310059867A CN 103690618 A CN103690618 A CN 103690618A
- Authority
- CN
- China
- Prior art keywords
- oil
- total saponins
- pulsatilla chinensis
- emulsion
- coemulsifier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the technical field of medicine, and relates to a pulsatilla chinensis total saponin oral emulsion and a preparation method thereof. The emulsion comprises the following components: 0.13%-13.5% of pulsatilla chinensis total saponins, 5%-50% of medicinal oil, 1%-30% of emulsifiers, 0-10% of auxiliary emulsifiers, 0.1%-15% of anti-oxidants, and the balance of purified water. The emulsion can be prepared by methods such as phase inversion emulsification method, PIT emulsification method, alternate liquid feeding emulsification method, ultrasonic wave emulsification method, low-energy emulsification method, micro-fluidization method, and the like. The pulsatilla chinensis total saponins provided by the invention are indissolvable drugs, and have irritation to gastrointestinal tracts. The dispersity of emulsion droplets in the emulsion is great, which facilitates drug absorption and increases bioavailability; the emulsion enables the drugs to be located in oil-water interfacial films or oil drop nuclei, which prevents direct contact of the drugs with gastrointestinal tracts, and thus reduces the gastrointestinal tract irritation of the drugs. The emulsion is a good carrier of pulsatilla chinensis total saponins; the addition of the auxiliary emulsifiers solves the problem of poor stability of common emulsions; when the emulsion is centrifuged at a rotating speed of 4000 r/min for 30 min, no layering phenomenon is caused; the bioavailability is high; and the stability is good.
Description
Technical field
The invention belongs to medical technical field, relate to total saponins of pulsatilla chinensis Orally taken emulsion and preparation method thereof.
Background technology
Cancer is one of serious disease of current harm humans life and health, World Health Organization's statistics shows, more than annual neopathy 1,000 ten thousand people of world's cancer, cancer accounts for total the more than 12% of death toll in the whole world, and in rising trend year by year, wherein nearly 60% is pulmonary carcinoma, hepatocarcinoma, gastric cancer, breast carcinoma, colorectal carcinoma, oral cancer, cervical cancer and the esophageal carcinoma, and malignant tumor is the major disease that threatens human life, finds antitumor drug efficient, low toxicity very urgent.
The Radix Pulsatillae " bitter in the mouth, temperature, nontoxic.The mad easy cold and heat of main pyrexial malaria, lump in the abdomen, tinea gas, by blood and relieving pain, incised wound ", wherein " lump in the abdomen " belongs to " tumor " category of modern medicine.Total saponins of pulsatilla chinensis is the effective site that the Radix Pulsatillae makes through extraction, separation and purification, modern pharmacological research shows that pulchinenoside has obvious inhibitory action to tumor, wherein, to people's hepatocarcinoma Bel-7402 and the nude mice effect of human lung adenocarcinoma A549 xenograft tumor and cyclophosphamide no significant difference, anxious poison experiment and general pharmacology are learned result of study and are shown that toxicity is lower.
At present domesticly yet there are no the research of total saponins of pulsatilla chinensis galenic pharmacy, because total saponins of pulsatilla chinensis dissolubility is little, absorption difference and gastrointestinal tract is had to zest, this will certainly limit its clinical practice.
Emulsion is owing to the not miscible two-phase system of script profit all can being changed into homogeneous liquid system relatively uniformly, its feature will be prepared into the preparation that a liquid form uniform, that the water of take is solution exists, beyond doubt a good dosage form for insoluble medicine.
Emulsion is the common dosage form of a class in galenic pharmacy, mostly generally is oil-in-water type (O/W), also has water-in-oil type (W/O), and only a few is shown in that compound is W/O/W type (W/O/W).The preparation of Emulsion generally all needs to use various types of surfactants that can effectively reduce interfacial tension, make the formed fine droplet surface tension of emulsifying be down to enough little, thereby the interior phase that makes fine droplet no longer because of interface break with foreign minister in the interior of other fine droplet merge mutually, could form so homodisperse two-phase or multiphase system of profit of a physically stable.
Orally taken emulsion is as the good carrier of gastrointestinal administration, and tool has the following advantages:
1, Emulsion peptizaiton is good, and effective surface area is large, is conducive to release, dissolving and the absorption of medicine;
2, in Emulsion, contain emulsifying agent, have surface-active action, can improve gastrointestinal mucosa performance, promote drug absorption;
3, after the fat absorption in Emulsion, can promote bile secretion, increase the flow velocity of blood and lymph fluid, contribute to medicine dissolution and absorption, the oil material in Emulsion also may be transported absorption by lymphsystem;
4, the oils and fats in Emulsion generates linoleic plus oleic acid after digestion, can suppress gastrointestinal and wriggle, and prolong drug is in the time of staying of small intestinal;
5, Orally taken emulsion can guarantee that dosage is accurate, and taking convenience, and oil-in-water emulsion can be covered the bad stink of fat-soluble medicine, also can add correctives;
6, Emulsion can make medicine be positioned in oil-water interfacial film or oil droplet core, avoid medicine directly to contact with gastrointestinal tract, thereby reduce medicine to gastrointestinal zest, avoid the common gastrointestinal reaction of general drug oral, as felt sick, vomiting, stomach burn, Upper abdominal pain, severe patient can cause the phenomenons such as polarity gastrointestinal hemorrhage and gastric ulcer to occur.
Therefore, the present invention develops the total saponins of pulsatilla chinensis Orally taken emulsion that a kind of low cost, preparation method are simple, have higher bioavailability.
Summary of the invention
Content of the present invention is to provide total saponins of pulsatilla chinensis Emulsion and preparation method.
Total saponins of pulsatilla chinensis Orally taken emulsion, its component and content are as follows: total saponins of pulsatilla chinensis 0.13%～13.5%(g/100 ml), medicinal sad certain herbaceous plants with big flowers acid triglyceride 5%～50% (g/100 ml), phosphatidase 11 %～30% (g/100 ml), Pluronic F68 0～10% (g/100 ml), vitamin E 0.1%～15% (g/100 ml), surplus is purified water.
Medicinal oil of the present invention is that a large class physiology can be accepted material, comprises one or more mixture of soybean oil, Oleum Ricini, Oleum Arachidis hypogaeae semen, Oleum sesami, Semen Maydis oil, Oleum Camelliae and artificial oil acetoacetic ester, butyl oleate; Soybean oil is selected from one or more the mixture in long chain triglyceride, medium chain triglyceride, glycerin mono-fatty acid ester, glycerol list linoleate.
Emulsifying agent of the present invention comprises one or more in nonionic emulsifier, anionic emulsifier and naturally occurring emulsifying agent.Nonionic emulsifier is selected from one or more of fatty acid Pyrusussuriensis smooth (being spans), Polysorbate (being Tweens), polyoxyethylene fatty acid ester class, polyoxyethylene aliphatic alcohol ether class, Pluronic F68 class, polyox-yethylene-polyoxypropylene block copolymer class, fatty acid monoglyceride, triglycerin fat acid esters, polyglyceryl fatty acid ester, sucrose fatty acid ester and glyceryl monostearate; Anionic emulsifier is selected from one or more mixture of sodium stearate, potassium stearate, enuatrol, potassium oleate, calcium stearate, sodium lauryl sulphate, hexadecyl hydrosulfate Oleum Ricini; Naturally occurring emulsifying agent is selected from one or more in arabic gum, tragakanta, gelatin and phospholipid.
Coemulsifier of the present invention comprises one or more in the coemulsifier that increases the coemulsifier of water viscosity and increase oil phase viscosity.The coemulsifier that increases water viscosity is selected from one or more in methylcellulose, Sodium Tvlose, carboxy-propyl cellulose, sodium alginate, agar, tragakanta, arabic gum, xanthan gum, guar gum, pectin, Bentonite; The coemulsifier that increases oil phase viscosity is selected from one or more mixture in spermol, Cera Flava, glyceryl monostearate, stearic acid, stearyl alcohol, glycerol, Polyethylene Glycol, polyglycerin ester, polyvidone.
Antioxidant of the present invention comprises one or more mixture of sodium sulfite, sodium sulfite, sodium thiosulfate, sodium pyrosulfite, ascorbic acid, propyl gallate, ascorbyl palmitate, butylated hydroxyarisol, ditertbutylparacresol, vitamin E.
In addition, the present invention also comprises the acceptable correctives of pharmacy, aromatic, antiseptic, viscosity modifier.
Emulsification method of the present invention can be selected phase conversion emulsifying, PIT emulsion process, replace liquid feeding emulsion process, ultrasonic emulsification, low-energy emulsification method, Micro Fluid method etc.
Emulsifying device of the present invention can be selected constant temperature blender with magnetic force, colloid mill, high speed dispersor, ultrasonic emulsator, high speed agitator, high pressure homogenizer etc.
A kind of be prepared of the present invention in can be as follows:
1, phase conversion emulsifying: get the oil-soluble composition mix homogeneously such as total saponins of pulsatilla chinensis, medicinal oil, emulsifying agent, antioxidant, make oil phase, 40～80 ℃ of insulations are standby; To after purified water and coemulsifier mixed dissolution, join in oil phase, 40～80 ℃ of lower magnetic forces stir 10～60 min, and high-speed shearing machine is sheared 1～30 min, embedding, and sterilizing, obtains product.
2, ultrasonic emulsification: get the oil-soluble composition mix homogeneously such as total saponins of pulsatilla chinensis, medicinal oil, emulsifying agent, antioxidant, make oil phase standby; To after purified water and coemulsifier mixed dissolution, join in oil phase, through ultrasonic emulsator, disperse, 100 W～1000 W, 1～5 min, in triplicate, and embedding, sterilizing, obtains product.
3, Micro Fluid method: get the oil-soluble composition mix homogeneously such as total saponins of pulsatilla chinensis, medicinal oil, emulsifying agent, antioxidant, 40～80 ℃ of preheatings, make oil phase standby; Under slowly stirring, in the mode of thin jet, the purified water that includes 0～10% coemulsifier of 40～80 ℃ of preheatings is joined in the oil phase of preheating, form stable O/W type Emulsion, embedding, sterilizing, obtains product.
Advantage of the present invention: the present invention can improve total saponins of pulsatilla chinensis bioavailability, total saponins of pulsatilla chinensis Orally taken emulsion is as gastrointestinal drug administration carrier, peptizaiton is good, effective surface area is large, be conducive to contain emulsifying agent in release, dissolving and the absorption of medicine and Emulsion, there is surface-active action, can improve gastrointestinal mucosa performance, thereby promote drug absorption to improve bioavailability.Adding of coemulsifier, has solved the problem of emulsion poor stability, and under the rotating speed of 4000 r/min, lamination, does not appear in centrifugal 30 min, and bioavailability is high, and good stability is easily taken by patient.
In order to reach object of the present invention, the present invention has carried out centrifugal stability test, isolated rat intestinal absorption test and pharmacokinetics test.
accompanying drawing explanation
With reference to accompanying drawing 1 and accompanying drawing 2.Accompanying drawing 1 and accompanying drawing 2 have shown that respectively the present invention is total saponins of pulsatilla chinensis Orally taken emulsion and tester total saponins of pulsatilla chinensis aqueous solution absorbing state and oral administration biaavailability situation in rat body.
As mentioned above, Emulsion of the present invention can make to absorb and improve in total saponins of pulsatilla chinensis body, and oral administration biaavailability significantly improves.
Following embodiment is used for being further explained in detail the present invention, but not as limitation of the scope of the invention.
The specific embodiment
Embodiment 1
Sad certain herbaceous plants with big flowers acid triglyceride (a) 10% (g/100 ml)
Total saponins of pulsatilla chinensis (b) 1.3% (g/100 ml)
Phospholipid (c) 5.4% (g/100 ml)
Vitamin E (d) 0.1% (g/100 ml)
PLURONICS F87 (e) 0.54% (g/100 ml)
Glycerol (f) 2.5% (g/100 ml)
Water (g) 70% (g/100 ml)
The oil-soluble composition mix homogeneously such as (a) and (b), (c), (d), make oil phase, and 40～80 ℃ of insulations are standby; By (e), (f) and (g), after mixed dissolution, join in oil phase, 40～80 ℃ of lower magnetic forces stir 10～60 min, and high-speed shearing machine is sheared 1～30 min, embedding, and sterilizing, obtains product.
Embodiment 2
Sad certain herbaceous plants with big flowers acid triglyceride (a) 20% (g/100 ml)
Total saponins of pulsatilla chinensis (b) 6.5% (g/100 ml)
Phospholipid (c) 10% (g/100 ml)
Vitamin E (d) 1% (g/100 ml)
PLURONICS F87 (e) 2% (g/100 ml)
Glycerol (f) 3% (g/100 ml)
Water (g) 80% (g/100 ml)
The oil-soluble composition mix homogeneously such as (a) and (b), (c), (d), make oil phase standby; By (e), (f) and (g), after mixed dissolution, join in oil phase, through ultrasonic emulsator, disperse, 100 W～1000 W, 1～5 min, in triplicate, and embedding, sterilizing, obtains product.
Embodiment 3
Sad certain herbaceous plants with big flowers acid triglyceride (a) 30% (g/100 ml)
Total saponins of pulsatilla chinensis (b) 13% (g/100 ml)
Phospholipid (c) 15% (g/100 ml)
Vitamin E (d) 2% (g/100 ml)
PLURONICS F87 (e) 4% (g/100 ml)
Glycerol (f) 5% (g/100 ml)
Water (g) 90% (g/100 ml)
The oil-soluble composition mix homogeneously such as (a) and (b), (c), (d), 40～80 ℃ of preheatings, make oil phase standby; Under slowly stirring, with the mode of thin jet by 40～80 ℃ of preheatings include (e) and purified water (f) joins in the oil phase of preheating, form stable O/W type Emulsion, embedding, sterilizing, obtains product.
Test example 1
The quality evaluation of Emulsion
According to the requirement of 2010 editions two appendix I0 Orally taken emulsion ruless of preparations of < < Pharmacopoeia of People's Republic of China > >, should not observe lamination with centrifugal 15 min of 4000 r/min.Get the prepared Emulsion of embodiment 15 ml in 5 ml centrifuge tubes, put in high speed centrifuge, centrifugal 15 min of 4000 r/min, stop rear taking-up Emulsion and observe, and have no lamination.Continue centrifugal to 30 min, the phenomenon of also not observing dispersed phase drop floating or sinking, the present invention is better than pharmacopeia oral latex emulsion rules of preparations specified standard.
Test example 2
For prediction is included in the oral absorbing state of pulchinenoside in Emulsion of the present invention, as follows the Emulsion of the present invention in embodiment 2, total saponins of pulsatilla chinensis aqueous solution are carried out respectively to the in vitro intestinal absorption research of medicine, prediction pulchinenoside absorbing state in vivo.With high efficiency liquid phase chromatographic analysis method, analyze the content of main component α-Hederagenin BD.
Get the male SD rat that body weight is about 250 g, be divided at random 2 groups, 6 every group.Fasting 24 h(freely feed water) after, urethane intraperitoneal injection of anesthesia with 20% (1.0 g/Kg body weight), opens abdominal cavity along ventrimeson, takes out experiment intestinal segment (approximately 10 cm), put into the blank K-R liquid of 37 ℃, remove mesentery and the fatty tissue on placenta percreta surface.Anus end is tightened with fine rule, with the thin Glass rod of round end by intestinal segment upset make mucous layer outside, placenta percreta is interior, intends forming enteric cavity, cleans content, stomach end colligation is nearly in sample tap (glass tubing one end).One group of intestinal capsule is placed in to the there-necked flask that fills 50 ml embodiment 2 Emulsions, another group is placed in and fills 50 ml total saponins of pulsatilla chinensis aqueous solutions, 37 ℃ of insulations in water-bath respectively.In intestinal capsule, fill with K-R liquid, and make the liquid level of CF body (being subject to medicine system) higher than the liquid level of the outer liquid of intestinal capsule (for medicine system).Continue to pass into mixture of oxygen (95% O
2, 5% CO
2), respectively at 0.5 h, 1 h, 1.5 h and 2 h, sample 1 ml, as need testing solution, stand-by, add the blank K-R liquid of 1 ml simultaneously.Get each need testing solution, add 5 ml chloroforms, vortex 40 min, centrifugal 15 min of 4000 r/min, get chloroform layer, evaporate to dryness chloroform, adds appropriate methanol and redissolves, and the liquid that redissolves is crossed 0.22 um microporous filter membrane, inject HPLC, sample introduction 10 ul, calculate the content of α-Hederagenin BD, record and the results are shown in Table-1 and figure-1.
Chromatographic condition is as follows: chromatographic column is Diamonsil C18 post (4.6 mm * 250 mm, 5 μ m), guard column C18 (4.0 mm * 3.0 mm), column temperature is 40 ℃, mobile phase acetonitrile-water-oxolane 52: 45:3 (V/V/V); Volume flow 1.0 ml/min, detects wavelength 203 nm, sample size 10 μ l.
Table-1 total saponins of pulsatilla chinensis Emulsion and aqueous solution BD intestinal absorption situation
As seen from the above table, the present invention compares with total saponins of pulsatilla chinensis aqueous solution, can improve the absorption of BD each intestinal segment in rat body, and check (P < 0.05), has significant difference between two groups by statistics.
Experimental example 3
For investigating, be included in the oral bioavailability of pulchinenoside in Emulsion of the present invention, as follows the Emulsion of the present invention in embodiment 3, total saponins of pulsatilla chinensis aqueous solution carried out respectively to pharmacokinetic study, evaluate pulchinenoside absorption in vivo.By mass spectrum-high performance liquid chromatography combination analysis method, analyze the content of main component α-Hederagenin BD.
Get the male SD rat that body weight is about 250 g, be divided at random 2 groups, 6 every group.Test front 12 h fasting, can freely drink water.Emulsion of the present invention in one group of oral administration gavage embodiment 3, another group oral administration gavage total saponins of pulsatilla chinensis aqueous solution, dosage is 70 mg/Kg rat body weights, after administration, respectively at 5,15,30,45,60,180,300,480,720,1440 min eye sockets, gets blood 0.4 ml, separated plasma, draw 500 ul, add acetonitrile 0.5 ml, vibration 2 min, centrifugal, get supernatant 10 ul sample introductions, record chromatogram and calculate the content of α-Hederagenin BD, record and the results are shown in Table-2 and figure-2.
Chromatographic condition is as follows: chromatographic column is Diamonsil C18 post (4.6 mm * 250 mm; 5 μ m); guard column C18 (4.0 mm * 3.0 mm), column temperature is 40 ℃, mobile phase acetonitrile-water-oxolane 52: 45: 3 (V/V/V); Volume flow 1.0 ml/min, detects wavelength 203 nm, sample size 10 μ l.
[0035] table-2 total saponins of pulsatilla chinensis Emulsions and aqueous solution BD blood drug level
As seen from the above table, the present invention compares with total saponins of pulsatilla chinensis aqueous solution, and in the present invention, BD blood drug level is 2～3 times of BD blood drug level in aqueous solution, can improve the bioavailability of BD, check (P < 0.05), has significant difference between two groups by statistics.
Claims (10)
1. total saponins of pulsatilla chinensis Emulsion is Orally taken emulsion, it is characterized in that: component percentage composition is: total saponins of pulsatilla chinensis is 0.13%～13.5%; Medicinal oil is 5%～50%; Emulsifying agent is 1%～30%; Coemulsifier is 0～10%; Antioxidant is 0.1%～15%; All the other are purified water.
2. total saponins of pulsatilla chinensis Orally taken emulsion according to claim 1, is characterized in that: its medicinal oil is vegetable oil, animal oil, mineral oil, quintessence oil and artificial oil.
3. total saponins of pulsatilla chinensis Orally taken emulsion according to claim 1, is characterized in that: vegetable oil is one or more mixture of soybean oil, Oleum Ricini, Oleum Arachidis hypogaeae semen, Oleum sesami, Semen Maydis oil, Oleum Camelliae and artificial oil acetoacetic ester, butyl oleate; Soybean oil is selected from one or more the mixture in long chain triglyceride, medium chain triglyceride, glycerin mono-fatty acid ester, glycerol list linoleate.
4. total saponins of pulsatilla chinensis Orally taken emulsion according to claim 1, it is characterized in that: its emulsifying agent is nonionic emulsifier, one or more in anionic emulsifier and naturally occurring emulsifying agent, nonionic emulsifier is selected from fatty acid Pyrusussuriensis smooth (being spans), Polysorbate (being Tweens), polyoxyethylene fatty acid ester class, polyoxyethylene aliphatic alcohol ether class, Pluronic F68 class, polyox-yethylene-polyoxypropylene block copolymer class, fatty acid monoglyceride, triglycerin fat acid esters, polyglyceryl fatty acid ester, one or more of sucrose fatty acid ester and glyceryl monostearate, anionic emulsifier is selected from one or more mixture of sodium stearate, potassium stearate, enuatrol, potassium oleate, calcium stearate, sodium lauryl sulphate, hexadecyl hydrosulfate Oleum Ricini, naturally occurring emulsifying agent is selected from one or more in arabic gum, tragakanta, gelatin and phospholipid.
5. total saponins of pulsatilla chinensis Orally taken emulsion according to claim 1, it is characterized in that: its coemulsifier is for increasing one or more in the coemulsifier of water viscosity and the coemulsifier of increase oil phase viscosity, and the coemulsifier that increases water viscosity is selected from one or more in methylcellulose, Sodium Tvlose, carboxy-propyl cellulose, sodium alginate, agar, tragakanta, arabic gum, xanthan gum, guar gum, pectin, Bentonite; The coemulsifier that increases oil phase viscosity is selected from one or more mixture in spermol, Cera Flava, glyceryl monostearate, stearic acid, stearyl alcohol, glycerol, Polyethylene Glycol, polyglycerin ester, polyvidone.
6. total saponins of pulsatilla chinensis Orally taken emulsion according to claim 1, is characterized in that: its antioxidant is one or more mixture of sodium sulfite, sodium sulfite, sodium thiosulfate, sodium pyrosulfite, ascorbic acid, propyl gallate, ascorbyl palmitate, butylated hydroxyarisol, ditertbutylparacresol, vitamin E.
7. total saponins of pulsatilla chinensis Orally taken emulsion according to claim 1, it is characterized in that: its optimum prescription is: total saponins of pulsatilla chinensis 0.13%～13.5%, medicinal sad certain herbaceous plants with big flowers acid triglyceride 5%～50%, phosphatidase 11 %～30%, Pluronic F68 0～10%, vitamin E 0.1%～15%.
8. preparation method-the phase conversion emulsifying of total saponins of pulsatilla chinensis Orally taken emulsion according to claim 1, it is characterized in that: get the oil-soluble composition mix homogeneously such as total saponins of pulsatilla chinensis, medicinal oil, emulsifying agent, antioxidant, obtain oil phase, 40～80 ℃ of insulations are standby; To after purified water and coemulsifier mixed dissolution, join in oil phase, 40～80 ℃ of lower magnetic forces stir 10～60 min, and high-speed shearing machine is sheared 1～30 min, embedding, and sterilizing, obtains product.
9. preparation method-the ultrasonic emulsification of total saponins of pulsatilla chinensis Orally taken emulsion according to claim 1, is characterized in that: get the oil-soluble composition mix homogeneously such as total saponins of pulsatilla chinensis, medicinal oil, emulsifying agent, antioxidant, obtain oil phase standby; To after purified water and coemulsifier mixed dissolution, join in oil phase, through ultrasonic emulsator, disperse, 100 W～1000 W, 1～5 min, in triplicate, and embedding, sterilizing, obtains product.
10. preparation method-Micro Fluid method of total saponins of pulsatilla chinensis Orally taken emulsion according to claim 1, is characterized in that: get the oil-soluble composition mix homogeneously such as total saponins of pulsatilla chinensis, medicinal oil, emulsifying agent, antioxidant, 40～80 ℃ of preheatings, obtain oil phase standby; Under slowly stirring, in the mode of thin jet, the purified water that includes 0～10% coemulsifier of 40～80 ℃ of preheatings is joined in the oil phase of preheating, obtain stable O/W type Emulsion, embedding, sterilizing, obtains product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310059867.XA CN103690618A (en) | 2013-02-26 | 2013-02-26 | Pulsatilla chinensis total saponin oral emulsion and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310059867.XA CN103690618A (en) | 2013-02-26 | 2013-02-26 | Pulsatilla chinensis total saponin oral emulsion and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103690618A true CN103690618A (en) | 2014-04-02 |
Family
ID=50352388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310059867.XA Pending CN103690618A (en) | 2013-02-26 | 2013-02-26 | Pulsatilla chinensis total saponin oral emulsion and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103690618A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940930A (en) * | 2015-05-31 | 2015-09-30 | 黑龙江佰彤儿童药物研究有限公司 | Oral medicine emulsion for treating pediatric epilepsy, and preparation method thereof |
| WO2018133108A1 (en) * | 2017-01-23 | 2018-07-26 | 四川英路维特医药科技有限公司 | Ziyuglycoside ii emulsion and preparation method therefor |
| CN109419864A (en) * | 2017-08-22 | 2019-03-05 | 北京中医药大学 | The new application of the Chinese bulbul |
| CN114642635A (en) * | 2020-12-18 | 2022-06-21 | 北京远大九和药业有限公司 | Oral emulsion of terpene medicinal composition, its preparation method and application |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1566136A (en) * | 2003-06-27 | 2005-01-19 | 吉林迈迪星药物科技发展有限公司 | Pasqueflower notoginsenosides and extraction method, medicinal uses and pharmaceutical preparation thereof |
-
2013
- 2013-02-26 CN CN201310059867.XA patent/CN103690618A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1566136A (en) * | 2003-06-27 | 2005-01-19 | 吉林迈迪星药物科技发展有限公司 | Pasqueflower notoginsenosides and extraction method, medicinal uses and pharmaceutical preparation thereof |
Non-Patent Citations (1)
| Title |
|---|
| 陆彬主编: "《药剂学》", 31 January 2003, 中国医药科技出版社 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940930A (en) * | 2015-05-31 | 2015-09-30 | 黑龙江佰彤儿童药物研究有限公司 | Oral medicine emulsion for treating pediatric epilepsy, and preparation method thereof |
| WO2018133108A1 (en) * | 2017-01-23 | 2018-07-26 | 四川英路维特医药科技有限公司 | Ziyuglycoside ii emulsion and preparation method therefor |
| CN109419864A (en) * | 2017-08-22 | 2019-03-05 | 北京中医药大学 | The new application of the Chinese bulbul |
| CN114642635A (en) * | 2020-12-18 | 2022-06-21 | 北京远大九和药业有限公司 | Oral emulsion of terpene medicinal composition, its preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhou et al. | Involvement of the inhibition of intestinal glucuronidation in enhancing the oral bioavailability of resveratrol by labrasol containing nanoemulsions | |
| Tang et al. | Mechanisms of microemulsion enhancing the oral bioavailability of puerarin: comparison between oil-in-water and water-in-oil microemulsions using the single-pass intestinal perfusion method and a chylomicron flow blocking approach | |
| US8835509B2 (en) | Self emulsifying drug delivery system for a curcuminoid based composition | |
| US20110092583A1 (en) | Oral Dosage Form Of Tetrahydrocannabinol And A Method Of Avoiding And/Or Suppressing Hepatic First Pass Metabolism Via Targeted Chylomicron/Lipoprotein Delivery | |
| EP2616053B1 (en) | Pharmaceutical compositions of curcumin | |
| WO2016022936A1 (en) | An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts | |
| PT1903866E (en) | Improved delivery of tetrahydrocannabinol | |
| CN101862306A (en) | New type slightly soluble oral medicine self-emulsification preparation and preparation method thereof | |
| WO2012033478A1 (en) | An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery | |
| JP2019163325A (en) | Composition comprising lipid compound, triglyceride, and surfactant, and methods of using the same | |
| Yin et al. | Self-nanoemulsifying drug delivery system of genkwanin: a novel approach for anti-colitis-associated colorectal cancer | |
| US20190224118A1 (en) | Oral gastroretentive formulations and uses thereof | |
| CN103690618A (en) | Pulsatilla chinensis total saponin oral emulsion and preparation method thereof | |
| KR20010093281A (en) | Spontaneously dispersible N-benzoyl staurosporine compositions | |
| US20030077303A1 (en) | New self emulsifying drug delivery system | |
| CN101390851A (en) | Double-cyclitol medicine composition containing surfactant and preparation method thereof | |
| EP1427392B1 (en) | New self emulsifying drug delivery system | |
| WO2006094829A1 (en) | Microemulsions of cannabinoid receptor binding compounds | |
| US20200215027A1 (en) | Dihydromyricetin nanoemulsion formulations and methods for forming them | |
| Maher et al. | Safety of surfactant excipients in oral drug formulations | |
| KR100712823B1 (en) | The solubilized coenzyme q10 soft capsules composition and the producing method thereof | |
| RU2397759C2 (en) | Microemulsion compositions including substance p antagonists | |
| CN1717219B (en) | Microemulsion composition for oral administration of biphenyldimethyldicarboxylate | |
| Hu et al. | Study on the inhibitory effects of naringenin-loaded nanostructured lipid carriers against nonalcoholic fatty liver disease | |
| CN102552820A (en) | Method of preparing soft capsule of lipid-lowering and removing obstruction in the collaterals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140402 |